Qrons Inc. has established a collaboration with scientists at a public research university in Israel, by which Tellurium-based compounds in combination with Qrons' QS-200 product candidate and other configurations will be explored as treatment for diffused axonal injuries (concussions), which accounts for approximately 89% of traumatic brain injuries (TBIs).

Everest Medicines Ltd. has achieved a preclinical proof-of-concept milestone for its mRNA rabies vaccine program. This new vaccine candidate for rabies post-exposure prophylaxis was developed in partnership with Providence Therapeutics Holdings Inc. utilizing a clinically validated mRNA technology platform.

Currently, most patients with urinary tract infections (UTIs) require long-term antibiotic treatment, which poses risks of resistance development and alters the patients' microbiota. Therefore, vaccines that raise safe, effective and long-lasting immune responses across populations for UTI prevention constitute a critical medical need. However, developing such vaccination strategies remains challenging because the responses need to be specific to a broad range of UTI-causing bacteria and include both blood and mucosal responses in the urogenital tract.

Both neutralizing antibodies and antibody effector functions are needed for protection against re-infection with respiratory syncytial virus (RSV), which may explain why it has been challenging to design an effective vaccine against the virus. As reported in the Dec. 12, 2022, issue of Cell, researchers carried out a human challenge study where volunteers were given a candidate vaccine for RSV, Ad26, or placebo.